Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Gene therapy eradicates pancreatic cancer in preclinical trial
Slashdot It! Slashdot Gene therapy eradicates pancreatic cancer in preclinical trial
Submit to Reddit Submit Gene therapy eradicates pancreatic cancer in preclinical trial to Reddit
Reading: Gene therapy eradicates pancreatic cancer in preclinical trialTwitter This Reading: Gene therapy eradicates pancreatic cancer in preclinical trialTwitter Gene therapy eradicates pancreatic cancer in preclinical trial
Add to Facebook Add Gene therapy eradicates pancreatic cancer in preclinical trial to Facebook

Gene therapy eradicates pancreatic cancer in preclinical trial

July 10, 2007

Targeting system's success in mouse model

HOUSTON -- A molecularly engineered therapy selectively embeds a gene in pancreatic cancer that shrinks or eradicates tumors, inhibits metastasis, and prolongs survival with virtually no toxicity, researchers from The University of Texas M. D. Anderson Cancer Center report in the July 9 edition of Cancer Cell.




"This vehicle, or vector, is so targeted and robust in its cancer-specific expression that it can be used for therapy and perhaps for imaging," notes senior author Mien-Chie Hung, Ph.D., professor and chair of M. D. Anderson's Department of Molecular and Cellular Oncology.

The researchers call the system a versatile expression vector - nicknamed VISA. It includes a targeting agent, also called a promoter, two components that boost gene expression in the target tissue, and a payload - in this case a gene known to kill cancer cells. It's all packaged in a fatty ball called a liposome and delivered intravenously.

Researchers are working with M. D. Anderson clinicians to move the system, developed and tested in mouse models of pancreatic cancer, to a Phase I clinical trial.

"This looks like a promising approach to gene therapy for pancreatic cancer and we are working to bring it to a clinical trial," says James Abbruzzese, M.D., professor and chair of the M. D. Anderson Department of Gastrointestinal Oncology.

He estimates that it will take between one and two years to complete U.S. Food and Drug Administration requirements for a Phase I trial. Abbruzzese's clinicians are working with Hung's group to compile preclinical information for FDA review.

About 37,000 cases of pancreatic cancer are diagnosed annually in the United States. Early diagnosis is extremely difficult, so the disease is often discovered at a late stage after it already has spread, or metastasized. Fewer than 4 percent of pancreatic cancer patients survive five years after diagnosis, one of the lowest cancer survival rates.

In a test of the therapy against two aggressive lines of pancreatic cancer in two different types of mice, researchers loaded the VISA system with a mutant version of a gene named Bik, which expresses a protein that naturally forces cancer cells to kill themselves. The team created the more lethal mutant and named it BikDD.

Untreated control mice in both experiments all died within 40 days. Mice treated with the mutant gene delivered via a less-targeted viral promoter driven expression system employing cytomegalovirus (CMV) all died within 90 days, most much earlier. In both trials, the VISA-BikDD mice lived longer, with at least half surviving for 14 months with no detectable sign of cancer recurrence.

One test involved a pancreatic cancer line that spreads swiftly. In that case, live imaging showed that in control mice the cancer spread to the liver, spleen, kidneys, bladder, lungs, bone and intestines. Mice treated with the CMV BikDD showed only a few small tumors in nearby organs. There were no detectable metastases in mice treated with the VISA-BikDD combination, the authors report.

"All cancer drugs have some toxicity and so cause side effects, which affects the dose that can be administered," Hung says. The team looked for signs of acute systemic toxicity and of pancreatitis, a dangerous inflammation of the pancreas. While the cytomegalovirus-BikDD showed signs of both toxicities, the authors report "VISA-BikDD produces virtually no systemically acute toxicity or acute pancreatitis."

Abbruzzese says any clinical trial will advance under a National Cancer Institute Specialized Programs of Research Excellence (SPORE) grant in pancreatic cancer. SPORE awards are designed to translate scientific findings into the clinic.

"There are no good options for pancreatic cancer patients now," says Abbruzzese, "That's why we are trying new approaches such as this one as part of SPORE."

Hung's team set out to address two obstacles to gene therapy for pancreatic cancer: lack of a targeted gene expression system that hits the cancer hard but spares normal tissue, and the need for an animal model that allows monitoring of tumor growth and metastasis without having to kill and dissect the animal.

They solved the monitoring problem by modifying two lines of pancreatic cancer to stably express firefly luciferace enzyme - the bioluminescent agent that lights up fireflies. This allowed live imaging of the mice to monitor cancer progression.

The researchers already had developed several components of the gene expression system. Led by first author Xiaoming Xie, Ph.D., a postdoctoral fellow and now instructor in Hung's department, the team used those components and pieces developed elsewhere to painstakingly build what became C-VISA-BikDD.

They used a gene-based targeting promoter called CCKAR known to be active in pancreatic cancer but not in healthy pancreatic tissue. The problem with pancreatic-cancer-specific gene promoters such as CCKAR, Hung says, is that they select narrowly for cancer cells but are not highly active once they get there. The success of gene therapy depends on efficient gene expression after delivery.

A system using a viral promoter such as CMV has the opposite problem: strong activity but indiscriminate delivery of the therapeutic gene to healthy tissue, which increases toxicity. The team's goal was to retain CCKAR's selectivity while boosting its activity to levels seen in CMV promoter-driven therapy.

To strengthen activity, the team added two key components: a regulatory gene sequence known as WPRE and the two-step transcriptional amplification system (TSTA) known to amplify activity of the prostate-specific antigen (PSA) promoter.

This enhanced C-VISA package increased gene activity levels by 67.6 percent to 287 percent over the CMV-driven therapy in three lines of pancreatic cancer. Lab experiments showed gene activity was limited to pancreatic cancer cells and was minimal or absent from other cancers and three lines of normal pancreatic, lung and breast cells.

The next step was to load the vector with a weapon. The team packaged its mutant version of the Bik gene along with C-VISA in a liposome. For comparison, the liposomal gene also was attached to the CMV vector.

They tested both systems in the lab against all 13 available human cell lines of pancreatic cancer available worldwide. BikDD killed cells in all lines, with the VISA-delivered gene destroying more cells in all but one case. The C-VISA system spared healthy tissue while CMV-BikDD destroyed healthy cells. Subsequent tests compared the two methods in the mouse models.

Hung's team continues research on gene expression vehicle. "VISA is versatile enough that if you change the promoter, you could target other cancers or even other diseases," Hung says.

University of Texas M. D. Anderson Cancer Center





Science News and Science Current Events Tag Cloud
This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
Lung Function   Radiation   Naltrexone   Smokers   Neurotransmitter   Neurons   Immunization   Human Migration   Botulinum Neurotoxin   Hydrothermal Vent   Abdominal Fat   Protein Folding   Diatoms   Fungus   Methane   Walking   Water Quality   AIDS vaccine   Cell Division   Biological Clock   Premature Birth   Marine Life   Climate Model   Memories   Mosquito  
Related Pancreatic Cancer Current Events and Pancreatic Cancer News Articles Pancreatic Cancer Current Events and Pancreatic Cancer News RSS Pancreatic Cancer Current Events and Pancreatic Cancer News RSS
Being overweight, obese during early adulthood associated with greater risk of pancreatic cancer
Young adults who are overweight or obese have an increased risk of pancreatic cancer, and being obese at an older age is associated with a lower overall survival rate for patients with pancreatic cancer.

M. D. Anderson study finds strong relationship between high body mass index, pancreatic cancer
In reviewing the weight history of pancreatic cancer patients across their life spans, researchers at The University of Texas M. D. Anderson Cancer Center have determined that a high body mass index in early adulthood may play a significant role in an individual developing the disease at an earlier age.

Adenoviral vector specifically targeted to EphA2 receptor in pancreatic cancer cells
Pancreatic cancer is a devastating disease with poor prognosis. This warrants the development of novel therapies including gene therapy.

Colon Cancer Screening Technique Shows Continued Promise in New Study
Recent clinical trials show that a new colon cancer screening technique created by Northwestern University researchers has a high enough sensitivity that it could potentially be as or more successful than a colonoscopy in screening for colon cancer.

Mayo Clinic finds new pathology tests double sensitivity to detect bile duct and pancreatic cancers
Pancreatic cancer and bile duct cancer are difficult to diagnose and often fatal because they are discovered in the advanced stages of the disease.

miR-196a promotes the metastases of tumors
MicroRNAs are small RNA molecules of 20-25 nucleotides length, regulating gene expression by inhibition of transcription or translation of proteins.

Popular diabetes treatment could trigger pancreatitis, pancreatic cancer
A drug widely used to treat Type 2 diabetes may have unintended effects on the pancreas that could lead to a form of low-grade pancreatitis in some patients and a greater risk of pancreatic cancer in long-term users, UCLA researchers have found.

Regulation of cell proliferation by the OGF-OGFr axis is dependent on nuclear localization signals
Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the efficacy of the Opioid Growth Factor (OGF, [Met5]-enkephalin), a clinically important antitumor agent, is dependent on nucleocytoplasmic translocation and reliant on the integrity of nuclear localization signals in the OGF receptor (OGFr).

Newly discovered epidermal growth factor receptor active in human pancreatic cancers
Finally some promising news about pancreatic cancer, one of the most fatal cancers, due to the difficulties of early detection and the lack of effective therapies: Johns Hopkins University pathologist Akhilesh Pandey has identified an epidermal growth factor receptor aberrantly active in approximately a third of the 250 human pancreatic cancers studied.

New drug achieves pancreatic cancer tumor remission and prevents recurrence
Pancreatic cancer remains one of the deadliest cancers, but researchers may have found a combination therapy to reduce cancer stem cells and stop pancreatic cancer growth. Results will be presented at the American Association for Cancer Research 100th Annual Meeting 2009.
More Pancreatic Cancer Current Events and Pancreatic Cancer News Articles
100 Q&A About Pancreatic Cancer (100 Questions & Answers)

100 Q&A About Pancreatic Cancer (100 Questions & Answers)
by Joanne Frankel Kelvin Eileen O'Reilly (Author)

EMPOWER YOURSELF! Whether you’re a newly diagnosed pancreatic cancer patient, a survivor, or a friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor’s and patient’s view, 100 Questions & Answers About Pancreatic Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. The authors, a medical oncologist and a nurse with 25 years of experience with cancer patients, provide a comprehensive, step-by-step discussion of what you can expect in the diagnosis and treatment of pancreatic cancer, while patient commentaries provide a real-life understanding of what these steps might mean for your day-to-day life. This book is an...

Pancreatic Cancer (M.D. Anderson Solid Tumor Oncology Series)

Pancreatic Cancer (M.D. Anderson Solid Tumor Oncology Series)
by Andrew M. Lowy (Editor), Steven D. Leach (Editor), Philip Philip (Editor)

Since the previous M.D. Anderson Solid Tumor Oncology Series publication on pancreatic cancer, there have been major advances in our understanding of molecular events which underlie pancreatic cancer development, both in the sporadic and inherited forms. We have seen the development of the first mouse models that accurately recapitulate features of the human disease. Several landmark clinical trials in both resectable and metastatic pancreatic cancer have been completed, raising new questions about the standard of care in this disease. Finally, the era of targeted biologic therapies has engendered new excitement about the prospects of more rapid progress in understanding and successfully treating this dreadful disease. Therefore, it is an appropriate time to review these important...

Pancreatic Cancer: Causes, Symptoms, Signs, Diagnosis, Treatments, Stages. Everything  You Need to Know About Pancreatic Cancer.

Pancreatic Cancer: Causes, Symptoms, Signs, Diagnosis, Treatments, Stages. Everything You Need to Know About Pancreatic Cancer.

Pancreatic Cancer: This book is for people who have pancreatic cancer (cancer of the pancreas), as well as for their family members, friends, students, and others who want to find out more about this disease. It will also give you pancreatic cancer signs and what to look for.

This National Cancer Institute (NCI) booklet has important information about cancer of the pancreas. In the United States, cancer of the pancreas is diagnosed in more than 29,000 people every year. It is the fifth leading cause of cancer death.
This booklet discusses possible causes of cancer of the pancreas. It also describes symptoms, diagnosis, treatment, and followup care. This information can help patients and their families better understand and cope with this disease.
Scientists are studying...

Pancreatic Cancer: Current and Emerging Trends in Detection and Treatment (Cancer and Modern Science)

Pancreatic Cancer: Current and Emerging Trends in Detection and Treatment (Cancer and Modern Science)
by Amy Sterling Casil (Author)



Clearly Charming Purple Ribbon Pancreatic Cancer, Fibromyalgia, Lupus Italian Charm

Clearly Charming Purple Ribbon Pancreatic Cancer, Fibromyalgia, Lupus Italian Charm

Purple ribbon stands for domestic violence, pancreatic cancer, Chrons Disease and colitis, Cystic Fibrosis, Fibromyalgia, and Lupus awareness. It will make a great addition to your Italian charm bracelet or a perfect personalized gift. Commemorate special occasions, capture memorable moments, or simply show off your birthstone by creating your own original Italian charm bracelet. Add Clearly Charming premium quality interlocking modular Italian charm links to your Italian Charm Bracelet and create your own memory bracelet.

Maximum Intenational Maximize Graviola 750, 750mg Graviola, 100 Veggie Caps

Maximum Intenational Maximize Graviola 750, 750mg Graviola, 100 Veggie Caps
by Maximum International

Having attracted worldwide interest as an inhibitor of malignant cell growth, this remarkable Amazonian herb has been studied in more than 20 laboratory tests for its anti-tumor and cell protective qualities. The best Graviola on the market. Maximum Int'l. is the company with the most potent products available. Lab tested to make sure the ingredients are of the most superior quality and highes quality raw materials available. This product is manufactured in an FDA inspected and GMP certified facility. Quality is guaranteed.

Cancer Be Gone

Cancer Be Gone

Guided imagery CD taps into the immense power of the mind to enhance comfort, healing, an optimistic attitude and positive expectations. Metaphor of "cancer as weeds in a garden that are easily managed".

Disease Essentials - Oncology: Pancreatic Cancer

Disease Essentials - Oncology: Pancreatic Cancer
by GeneEd E-Learning

This electronic book (PDF format) provides a medical background on the cause, diagnosis, and treatment of the most common types of pancreatic cancer. This book is divided into 6 sections: The first section, ANATOMY AND PHYSIOLOGY, describes the pancreas and explains its function. The second section, PATHOPHYSIOLOGY, discusses the common types of pancreatic cancer. The third section, EPIDEMIOLOGY, introduces epidemiological data on pancreatic cancer in the US and worldwide and discusses common risk factors for pancreatic cancer. The fourth section, DIAGNOSIS AND STAGING, describes the diagnosis and staging of the most common types of pancreatic cancer, including the symptoms of pancreatic cancer, common methods used in diagnosis, and the TNM classification system. The fifth section,...

Pancreatic Cancer Awareness Ribbon Mouse Pad

Pancreatic Cancer Awareness Ribbon Mouse Pad
by MyHeritageWear.com

The Pancreatic Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Pancreatic Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Pancreatic Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness!

Beating Pancreatic Cancer Together T-shirt Large White

Beating Pancreatic Cancer Together T-shirt Large White



© 2009 BrightSurf.com